TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth
TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth Investing.com India
Covered in this story
What has happened since
- Abbott Laboratories is down 14.6% since this was published, 49 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
TD Cowen’s $135 target on $ABT is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
TD Cowen’s track record →Analyst targets on Abbott Laboratories
- Rothschild & Co Redburn: $97.5 → $127 by Oct 2027 via Investing.com
- UBS: $107 → $125 by Jul 2027 via GuruFocus
- Citi: $101 → $112 by Jul 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abbott Laboratories →Dalsna Finance is currently tracking 46 stories mentioning Abbott Laboratories, the earliest published 22 May 2026.
Summary aggregated from Investing.com India's public RSS feed. The full reporting belongs to Investing.com India — please read it on their site.